Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-man 13N-Oxytocin PET Imaging
NCT06955650Phase 1Completed
- Sponsor
- Aarhus University Hospital
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 13N-oxytocin in Facial pain, sponsored by Aarhus University Hospital. Primary endpoint: Radiation dosimetry of 13N-Oxytocin calculated using MIRDcalc at 14 days. Started Apr 2021; status: completed.
02
Drugs
13N-oxytocin
03
Conditions
Facial pain
Beyond the preview
Go deeper on NCT06955650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955650.